{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:39:20Z","timestamp":1788485960314,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"DOI":"10.7759\/cureus.65792","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:45:56Z","timestamp":1722386756000},"source":"Crossref","is-referenced-by-count":1,"title":["Characterizing Myasthenia Gravis Symptoms, Exacerbations, and Crises From Neurologist's Clinical Notes Using Natural Language Processing"],"prefix":"10.7759","author":[{"given":"Jonathan D","family":"Darer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Pesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto E","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Parab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081736","article-title":"Diagnosis of myasthenia gravis","volume":"10","author":"Rousseff RT","year":"2021","unstructured":"Rousseff RT. Diagnosis of myasthenia gravis. J Clin Med. 2021, 10:10.3390\/jcm10081736","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth A","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012, 2012:874680. 10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000512077","article-title":"Exacerbation rate in generalized myasthenia gravis and its predictors","volume":"84","author":"Abuzinadah AR","year":"2021","unstructured":"Abuzinadah AR, Alanazy MH, Butt NS, Barohn RJ, Dimachkie MM. Exacerbation rate in generalized myasthenia gravis and its predictors. Eur Neurol. 2021, 84:43-8. 10.1159\/000512077","journal-title":"Eur Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00285-w","article-title":"The lived experience of myasthenia gravis: a patient-led analysis","volume":"10","author":"Law N","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021, 10:1103-25. 10.1007\/s40120-021-00285-w","journal-title":"Neurol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03185-7","article-title":"Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis","volume":"19","author":"Salari N","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, et al.. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021, 19:516. 10.1186\/s12967-021-03185-7","journal-title":"J Transl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids","volume":"30","author":"Tannemaat MR","year":"2020","unstructured":"Tannemaat MR, Verschuuren JJ. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscul Disord. 2020, 30:111-9. 10.1016\/j.nmd.2019.12.003","journal-title":"Neuromuscul Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer S","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, et al.. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol. 2022, 269:3050-63. 10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538","article-title":"Fatigue in myasthenia gravis: risk factors and impact on quality of life","volume":"6","author":"Hoffmann S","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016, 6:e00538. 10.1002\/brb3.538","journal-title":"Brain Behav"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks TM","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019, 205:99-105. 10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser L","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021, 10:10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold C","year":"2021","unstructured":"Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 2021, 14:17562864211065406. 10.1177\/17562864211065406","journal-title":"Ther Adv Neurol Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza R","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018, 11:1756285617749134. 10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold C","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019, 12:1756286419832242. 10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson DL","year":"1997","unstructured":"Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997, 84:223-43. 10.1006\/clin.1997.4412","journal-title":"Clin Immunol Immunopathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6808","article-title":"Myasthenia gravis with elderly onset at advanced age","volume":"12","author":"Hernandez Fustes OJ","year":"2020","unstructured":"Hernandez Fustes OJ, Arteaga Rodriguez C, Hernandez Fustes OJ. Myasthenia gravis with elderly onset at advanced age. Cureus. 2020, 12:e6808. 10.7759\/cureus.6808","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell LC","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011, 1:16-22. 10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.08.008","article-title":"Predictors of outcome in patients with myasthenic crisis undergoing non-invasive mechanical ventilation: A retrospective 20 year longitudinal cohort study from a single Italian center","volume":"31","author":"Iori E","year":"2021","unstructured":"Iori E, Mazzoli M, Ariatti A, et al.. Predictors of outcome in patients with myasthenic crisis undergoing non-invasive mechanical ventilation: A retrospective 20 year longitudinal cohort study from a single Italian center. Neuromuscul Disord. 2021, 31:1241-50. 10.1016\/j.nmd.2021.08.008","journal-title":"Neuromuscul Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi T","year":"2016","unstructured":"Akaishi T, Suzuki Y, Imai T, et al.. Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol. 2016, 16:225. 10.1186\/s12883-016-0756-3","journal-title":"BMC Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-1036. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/aian.AIAN_595_19","article-title":"Myasthenia gravis: do the subtypes matter?","volume":"23","author":"Murthy JM","year":"2020","unstructured":"Murthy JM. Myasthenia gravis: do the subtypes matter?. Ann Indian Acad Neurol. 2020, 23:2. 10.4103\/aian.AIAN_595_19","journal-title":"Ann Indian Acad Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer N","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et al.. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016, 263:1473-94. 10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al.. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016, 87:419-25. 10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman R","year":"1997","unstructured":"Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997, 244:112-8. 10.1007\/s004150050059","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt E","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020, 38:715-28. 10.1007\/s40273-020-00912-8","journal-title":"Pharmacoeconomics"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8497","article-title":"Myasthenia gravis","volume":"345","author":"Spillane J","year":"2012","unstructured":"Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ. 2012, 345:e8497. 10.1136\/bmj.e8497","journal-title":"BMJ"},{"key":"ref26","article-title":"Introductory Chapter: Myasthenia Gravis - An Overview","author":"AL-Zwaini J","unstructured":"AL-Zwaini J, AL-Mayahi A. Introductory Chapter: Myasthenia Gravis - An Overview. Selected Topics in Myasthenia Gravis. IntechOpen,"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri NJ","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014, 15:167-78. 10.1097\/CND.0000000000000034","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","author":"Engel-Nitz NM","year":"2018","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018, 10.1002\/mus.26114","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris L","year":"2022","unstructured":"Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S. A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol. 2022, 22:172. 10.1186\/s12883-022-02692-4","journal-title":"BMC Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9367453","article-title":"Prevalence and associated factors of depressive symptoms in patients with myasthenia gravis: a cross-sectional study of two tertiary hospitals in Riyadh, Saudi Arabia","volume":"2019","author":"Alanazy MH","year":"2019","unstructured":"Alanazy MH. Prevalence and associated factors of depressive symptoms in patients with myasthenia gravis: a cross-sectional study of two tertiary hospitals in Riyadh, Saudi Arabia. Behav Neurol. 2019, 2019:9367453. 10.1155\/2019\/9367453","journal-title":"Behav Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9184","article-title":"A review of psychiatric comorbidity in myasthenia gravis","volume":"12","author":"Law C","year":"2020","unstructured":"Law C, Flaherty CV, Bandyopadhyay S. A review of psychiatric comorbidity in myasthenia gravis. Cureus. 2020, 12:e9184. 10.7759\/cureus.9184","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/NNR.0000000000000488","article-title":"Identifying symptom information in clinical notes using natural language processing","volume":"70","author":"Koleck TA","year":"2021","unstructured":"Koleck TA, Tatonetti NP, Bakken S, et al.. Identifying symptom information in clinical notes using natural language processing. Nurs Res. 2021, 70:173-83. 10.1097\/NNR.0000000000000488","journal-title":"Nurs Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2196\/12239","article-title":"Natural language processing of clinical notes on chronic diseases: systematic review","volume":"7","author":"Sheikhalishahi S","year":"2019","unstructured":"Sheikhalishahi S, Miotto R, Dudley JT, Lavelli A, Rinaldi F, Osmani V. Natural language processing of clinical notes on chronic diseases: systematic review. JMIR Med Inform. 2019, 7:e12239. 10.2196\/12239","journal-title":"JMIR Med Inform"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocv180","article-title":"Extracting information from the text of electronic medical records to improve case detection: a systematic review","volume":"23","author":"Ford E","year":"2016","unstructured":"Ford E, Carroll JA, Smith HE, Scott D, Cassell JA. Extracting information from the text of electronic medical records to improve case detection: a systematic review. J Am Med Inform Assoc. 2016, 23:1007-15. 10.1093\/jamia\/ocv180","journal-title":"J Am Med Inform Assoc"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2017.11.011","article-title":"Clinical information extraction applications: A literature review","volume":"77","author":"Wang Y","year":"2018","unstructured":"Wang Y, Wang L, Rastegar-Mojarad M, et al.. Clinical information extraction applications: A literature review. J Biomed Inform. 2018, 77:34-49. 10.1016\/j.jbi.2017.11.011","journal-title":"J Biomed Inform"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.946387","article-title":"Natural language processing in clinical neuroscience and psychiatry: A review","volume":"13","author":"Crema C","year":"2022","unstructured":"Crema C, Attardi G, Sartiano D, Redolfi A. Natural language processing in clinical neuroscience and psychiatry: A review. Front Psychiatry. 2022, 13:946387. 10.3389\/fpsyt.2022.946387","journal-title":"Front Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-017-0418-4","article-title":"Early recognition of multiple sclerosis using natural language processing of the electronic health record","volume":"17","author":"Chase HS","year":"2017","unstructured":"Chase HS, Mitrani LR, Lu GG, Fulgieri DJ. Early recognition of multiple sclerosis using natural language processing of the electronic health record. BMC Med Inform Decis Mak. 2017, 17:24. 10.1186\/s12911-017-0418-4","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/s0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki A 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al.. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000, 70:327-334. 10.1016\/s0003-4975(00)01595-2","journal-title":"Ann Thorac Surg"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke C","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C, et al.. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation. 2022, 19:89. 10.1186\/s12974-022-02448-4","journal-title":"J Neuroinflammation"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips G","year":"2021","unstructured":"Phillips G, Abreu C, Goyal A, et al.. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2021, 12:809999. 10.3389\/fneur.2021.809999","journal-title":"Front Neurol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-15-130","article-title":"The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review","volume":"15","author":"Lebeau JP","year":"2014","unstructured":"Lebeau JP, Cadwallader JS, Aubin-Auger I, et al.. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract. 2014, 15:130. 10.1186\/1471-2296-15-130","journal-title":"BMC Fam Pract"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0029","article-title":"Overview of therapeutic inertia in diabetes: prevalence, causes, and consequences","volume":"33","author":"Karam SL","year":"2020","unstructured":"Karam SL, Dendy J, Polu S, Blonde L. Overview of therapeutic inertia in diabetes: prevalence, causes, and consequences. Diabetes Spectr. 2020, 33:8-15. 10.2337\/ds19-0029","journal-title":"Diabetes Spectr"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09979-z","article-title":"Clinical inertia in the treatment of heart failure: a major issue to tackle","volume":"26","author":"Verhestraeten C","year":"2021","unstructured":"Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2021, 26:1359-70. 10.1007\/s10741-020-09979-z","journal-title":"Heart Fail Rev"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2018.04.002","article-title":"Factors promoting clinical inertia in caring for patients with dyslipidemia: a consensual study among clinicians who provide healthcare to patients with dyslipidemia","volume":"111","author":"Shawahna R","year":"2019","unstructured":"Shawahna R, Odeh M, Jawabreh M. Factors promoting clinical inertia in caring for patients with dyslipidemia: a consensual study among clinicians who provide healthcare to patients with dyslipidemia. J Natl Med Assoc. 2019, 111:18-27. 10.1016\/j.jnma.2018.04.002","journal-title":"J Natl Med Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/242570-characterizing-myasthenia-gravis-symptoms-exacerbations-and-crises-from-neurologists-clinical-notes-using-natural-language-processing","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:46:00Z","timestamp":1722386760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/242570-characterizing-myasthenia-gravis-symptoms-exacerbations-and-crises-from-neurologists-clinical-notes-using-natural-language-processing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.65792","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}